The pathophysiologic approach to the inhibition of FXI make it a promising target to solve the prothrombotic situations encountered with patients with a cancer-mediated procoagulant state (e.g., during chemotherapy, malignancy, or catheter placement). The gene discussed is F11; the disease is cancer.